Abstract
Fifty-five evaluable patients with disseminated malignant melanoma were treated with the combination of dacarbazine (DTIC) 400 mg i.v. on days 1 to 3 and lomustine (CCNU) 50 to 80 mg m-2 orally on day 1 with intervals of 6 weeks as the first line chemotherapy. Three (5%) patients had complete and 6 (11%) partial response, and 7 (13%) patients had stable disease at least for 3 months. The patients with an objective response (n = 9) survived longer than the rest of the patients if the length of survival was calculated from the start of chemotherapy (P = 0.0006). However, the responding patients also had longer time interval from the diagnosis to the detection of distant metastases (P = 0.05), and survival time from disease progression following DTIC and CCNU therapy (P = 0.005). These findings suggest that patients with an objective response to DTIC-CCNU therapy have melanoma with a slow progression rate, and prolonged survival in such patients may in part result from the less aggressive biological nature of their tumours.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ahmann D. L., Creagan E. T., Hahn R. G., Edmonson J. H., Bisel H. F., Schaid D. J. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer. 1989 Jan 15;63(2):224–227. doi: 10.1002/1097-0142(19890115)63:2<224::aid-cncr2820630203>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
- Anderson J. R., Cain K. C., Gelber R. D. Analysis of survival by tumor response. J Clin Oncol. 1983 Nov;1(11):710–719. doi: 10.1200/JCO.1983.1.11.710. [DOI] [PubMed] [Google Scholar]
- Comis R. L. DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep. 1976 Feb;60(2):165–176. [PubMed] [Google Scholar]
- Joensuu H., Asola R., Minn H. Combination chemotherapy with dacarbazine and lomustine in disseminated malignant melanoma. Acta Radiol Oncol. 1986 May-Jun;25(3):177–179. doi: 10.3109/02841868609136399. [DOI] [PubMed] [Google Scholar]
- Lakhani S., Selby P., Bliss J. M., Perren T. J., Gore M. E., McElwain T. J. Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer. 1990 Feb;61(2):330–334. doi: 10.1038/bjc.1990.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Legha S. S. Current therapy for malignant melanoma. Semin Oncol. 1989 Feb;16(1 Suppl 1):34–44. [PubMed] [Google Scholar]
- Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
- Pectasides D., Yianniotis H., Alevizakos N., Bafaloukos D., Barbounis V., Varthalitis J., Dimitriadis M., Athanassiou A. Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin. Br J Cancer. 1989 Oct;60(4):627–629. doi: 10.1038/bjc.1989.327. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Seigler H. F., Lucas V. S., Jr, Pickett N. J., Huang A. T. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer. 1980 Dec 1;46(11):2346–2348. doi: 10.1002/1097-0142(19801201)46:11<2346::aid-cncr2820461104>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
- Thatcher D., Lind M., Morgenstern G., Carr T., Chadwick G., Jones R., Craig P. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Cancer. 1989 Apr 1;63(7):1296–1302. doi: 10.1002/1097-0142(19890401)63:7<1296::aid-cncr2820630712>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
- York R. M., Foltz A. T. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer. 1988 Jun 1;61(11):2183–2186. doi: 10.1002/1097-0142(19880601)61:11<2183::aid-cncr2820611108>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
- Young D. W., Lever R. S., English J. S., MacKie R. M. The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. Cancer. 1985 May 1;55(9):1879–1881. doi: 10.1002/1097-0142(19850501)55:9<1879::aid-cncr2820550906>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]